The phase-3 VELOUR study tested FOLFIRI ± Zaltrap in patients who had progressed on FOLFOX in the first-line setting. SNY/REGN reported in April that this study hit its OS primary endpoint (#msg-62465993), but the hazard ratios and p-values were unknown until today. Description of the VELOUR study is at http://clinicaltrials.gov/ct2/show/NCT00561470 . Full data will be reported at ESMO on 6/25/11.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.